

## MPNs and GVHD

|   |   | Clinical Proof of Concept | Pivotal | Approved |
|---|---|---------------------------|---------|----------|
| <b>Jakafi® (ruxolitinib)</b> <sup>1</sup> JAK1/JAK2 | Myelofibrosis <sup>2</sup> , polycythemia vera <sup>2</sup> , GVHD <sup>2</sup> |                           |         |          |
| <b>ruxolitinib XR (QD)</b> JAK1/JAK2                | Bioequivalence and stability testing  |                           |         |          |
| <b>axatilimab</b> <sup>3</sup> CSF-1R               | 3L+ chronic GVHD  |                           |         |          |
|   | 1L chronic GVHD   + ruxolitinib   |                           |         |          |
| <b>zilurgisertib</b> ALK2                           | Myelofibrosis-associated anemia   ± ruxolitinib                                 |                           |         |          |
| <b>INCB57643</b> BET                                | Myelofibrosis   ± ruxolitinib   |                           |         |          |
| <b>INCA33989</b> mutCALR                            | Myelofibrosis or ET with CALR mutation   ± ruxolitinib                          |                           |         |          |
| <b>INCB160058</b> JAK2 <sup>V617F</sup>             | JAK2 <sup>V617F</sup> -mutated myelofibrosis                                    |                           |         |          |

## Dermatology and Other IAI

|  |   |  |  |  |
|--|---|--|--|--|
| <b>Opzelura® (ruxolitinib) cream</b> JAK1/JAK2 | AD <sup>2</sup> , vitiligo <sup>2,4</sup>                 |  |  |  |
| <b>ruxolitinib cream</b> JAK1/JAK2             | Pediatric AD, prurigo nodularis                           |  |  |  |
|  | Hidradenitis suppurativa, lichen planus, lichen sclerosus |  |  |  |
| <b>povorcitinib</b> JAK1                       | Hidradenitis suppurativa, vitiligo                        |  |  |  |
|  | Prurigo nodularis, chronic spontaneous urticaria, asthma  |  |  |  |
| <b>zilurgisertib</b> ALK2                      | Fibrodysplasia ossificans progressiva                     |  |  |  |

## Partnered Programs

|   |  |  |  |  |
|---|--|--|--|--|
| <b>Olumiant® (baricitinib)</b> <sup>5</sup> JAK1/JAK2 | Rheumatoid arthritis <sup>6</sup> , COVID-19 <sup>6</sup> , AD <sup>4,7</sup> , alopecia areata <sup>2,4,7</sup> |  |  |  |
| <b>Tabrecta® (capmatinib)</b> <sup>8</sup> MET        | NSCLC with METex14 <sup>6</sup>  |  |  |  |
| <b>capmatinib</b> <sup>8</sup> MET                    | Liver cancer   |  |  |  |
| <b>axatilimab</b> CSF-1R                              | Idiopathic pulmonary fibrosis <sup>9</sup>   |  |  |  |

## General Hematology/Oncology

|  |   | Clinical Proof of Concept | Pivotal | Approved |
|--|---|---------------------------|---------|----------|
| <b>Pemazyre® (pemigatinib)</b> FGFR1/2/3   | 2L+ cholangiocarcinoma <sup>10</sup> , MLNs with FGFR1 rearrangement <sup>2,7</sup> |                           |         |          |
| <b>Monjuvi® (tafasitamab-cxix)</b><br><b>Minjuvi® (tafasitamab)</b> CD19                           | r/r DLBCL <sup>2,4,11</sup>   |                           |         |          |
| <b>Iclusig® (ponatinib)</b> <sup>12</sup> BCR-ABL  | Chronic myeloid leukemia <sup>4</sup> , Ph+ ALL <sup>4</sup>                        |                           |         |          |
| <b>Zynyz® (retifanlimab-dlwr)</b> <sup>13</sup><br><b>Zynyz® (retifanlimab)</b> <sup>13</sup> PD-1 | Merkel cell carcinoma <sup>2,4</sup>  |                           |         |          |
| <b>pemigatinib</b> FGFR1/2/3   | 1L cholangiocarcinoma   |                           |         |          |
|  | Glioblastoma  |                           |         |          |
| <b>tafasitamab</b> CD19  | 1L DLBCL, r/r follicular lymphoma, r/r MZL  |                           |         |          |
| <b>retifanlimab</b> <sup>13</sup> PD-1 (mAb)   | Squamous cell anal carcinoma, NSCLC   |                           |         |          |
|  | MSI-H endometrial cancer  |                           |         |          |
| <b>itacitinib</b> JAK1   | Cytokine release syndrome   |                           |         |          |
| <b>INCB99280</b> PD-L1 (small molecule)  | Cutaneous squamous cell carcinoma, solid tumors                                     |                           |         |          |
| <b>INCB99318</b> PD-L1 (small molecule)  | Solid tumors  |                           |         |          |
| <b>INCAGN2385</b> <sup>14</sup> LAG-3  | Solid tumors  |                           |         |          |
| <b>INCAGN2390</b> <sup>14</sup> TIM-3  | Solid tumors  |                           |         |          |
| <b>INCA32459</b> <sup>15</sup> LAG-3×PD-1  | Advanced malignancies   |                           |         |          |
| <b>INCA33890</b> <sup>15</sup> TGFβR2×PD-1   | Solid tumors  |                           |         |          |
| <b>INCB123667</b> CDK2   | Solid tumors  |                           |         |          |
| <b>INCB161734</b> KRAS <sup>G12D</sup>   | KRAS <sup>G12D</sup> -mutated solid tumors  |                           |         |          |

19 Molecular Targets

24 Clinical Compounds

8 Approved Products

Updated as of April 30, 2024

Please refer to local prescribing information for more information, including full safety information, on Incyte's marketed medicines, or on medicines marketed by Incyte's collaboration partners.

1. Marketed by Incyte in the U.S.; ruxolitinib licensed to Novartis outside the U.S. 2. Approved in the U.S. 3. In collaboration with Syndax 4. Approved in Europe 5. Worldwide rights to baricitinib licensed to Lilly 6. Approved in multiple territories globally 7. Approved in Japan 8. Worldwide rights to capmatinib licensed to Novartis 9. IPF study currently led and funded by Syndax 10. Approved in multiple territories, including the U.S., Canada, Europe, and Japan 11. Approved in Canada 12. European rights to Iclusig licensed from Takeda 13. Licensed from MacroGenics 14. Discovery collaboration with Agenus 15. Development in collaboration with Merus

1L, first-line; 2L+, second-line or later; 3L+, third-line or later; AD, atopic dermatitis; ALL, acute lymphoblastic leukemia; DLBCL, diffuse large B-cell lymphoma; ET, essential thrombocythemia; FGFR, fibroblast growth factor receptor; GVHD, graft-versus-host disease; IAI, inflammation and autoimmunity; IPF, idiopathic pulmonary fibrosis; mAb, monoclonal antibody; MLNs, myeloid/lymphoid neoplasms; MPNs, myeloproliferative neoplasms; MSI-H, microsatellite instability-high; mut, mutant; MZL, marginal zone lymphoma; NSCLC, non-small cell lung cancer; Ph+, Philadelphia chromosome-positive; QD, once daily; r/r, relapsed or refractory; XR, extended release.